NCT06191120View on ClinicalTrials.gov

FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype

NANot yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

July 31, 2031

Conditions
Metastatic Colorectal CancerMetastatic Cancer to Liver
Interventions
RADIATION

[18F]-ALF-FAPI-74 PET/CT scan

Participants will receive up to three \[18F\]-ALF-FAPI-74 PET/CT scans. \[18F\]-ALF-FAPI-74 is a PET tracer with high binding specificity and selectivity to FAP-expressing cells.

All Listed Sponsors
lead

UMC Utrecht

OTHER

NCT06191120 - FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype | Biotech Hunter | Biotech Hunter